Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Review it before choosing a plan
However, CMS clarified in a memo dated March 20, 2024, that anti-obesity medications that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use. As of August 19, 2024, the only GLP-1 RA this applies to is Wegovy, which, in addition to its obesity indication, is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
Talk with a licensed clinician about severe, persistent, unusual, or concerning symptoms
For the broader picture of which peptides already have FDA approval, see our FDA Approved Peptides List 2026
Tapering vs
US$ 28.66
US$ 22.04
US$ 29.02
US$ 23.29
US$ 26.99
US$ 21.63
